TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01793961

Intervention type: OTHER
Group type: OTHER
Intervention: electroretinogram
Study: NCT01060774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Up to 5 capsules of 0.5% Bupivacaine with epinephrine given post-operatively.
Study: NCT00968383

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta adrenergic blockers
Description: Participants will receive beta adrenergic blockers.
Study: NCT00968383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta adrenergic blockers
Description: Participants will receive beta adrenergic blockers.
Study: NCT00448786

Intervention type: DRUG
Group type: OTHER
Intervention: AMG 706
Description: AMG 706 125 mg daily continuously (Arm A)
Study: NCT02857309

Intervention type: DEVICE
Group type: OTHER
Intervention: OPTIMIZER
Description: The OPTIMIZER System delivers non-excitatory cardiac contractility modulation (CCM) signals to the heart that are intended to influence myocardial properties in patients with chronic heart failure. The system has no pacemaker or implantable cardioverter-defibrillator (ICD) functions.
Study: NCT00968383

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet inhibitors
Description: Participants will receive platelet inhibitors.
Study: NCT01793961

Intervention type: OTHER
Group type: OTHER
Intervention: electroretinogram

Intervention type: OTHER
Group type: OTHER
Intervention: contrast sensitivity tests

Intervention type: OTHER
Group type: OTHER
Intervention: contrast sensitivity tests

Intervention type: OTHER
Group type: OTHER
Intervention: contrast sensitivity tests
Study: NCT02177526

Intervention type: DEVICE
Group type: OTHER
Intervention: Imaging
Description: 15 patients with malignant comedo-type necrosis and calcifications detected with histo-pathology from guided biopsies will be enrolled after obtaining informed consent. 15 patients with biopsy proven Gleason pattern 5 tumor and without comedo-type necrosis associated calcification will serve as a comparison group after providing informed consent for a total of 30 patients.
Study: NCT02401490

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human albumin
Description: 1.5gr/Kg/day at least in the 24-48 hours after the hospitalization and 1.0 gr/Kg/day at 72 hours after the first dose.
Study: NCT00968383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet inhibitors
Description: Participants will receive platelet inhibitors.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statins
Description: Participants will receive statins.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins
Description: Participants will receive statins.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE inhibitors and/or ARB and/or AA
Description: Participants will receive ACE inhibitors and/or ARB and/or AA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE inhibitors and/or ARB and/or AA
Description: Participants will receive ACE inhibitors and/or ARB and/or AA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI with stenting
Description: Participants will undergo percutaneous coronary intervention (PCI) and coronary stenting.
Study: NCT03867747

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cardiac Radiosurgery
Description: Image-guided stereotactic body radiation therapy
Study: NCT00071721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Description: 250mg tablets beginning with one daily for one week, then two daily for one week, then titrated according to body weight and tolerability to achieve 10-12 mg/kg daily for 2 years, followed by a 2-month washout

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets beginning with one daily and increasing according to weight and perceived tolerability concerns for two years, followed by a 2-month washout
Study: NCT00791843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone releasing hormone/ placebo
Description: 12 weeks of drug at max dose of 2mg/day administered in 4 pulses at 11pm, 1am, 3am, and 5am, followed by 6 weeks of washout period, then 12 weeks of placebo or vise versa- 12 weeks of placebo, 6 weeks washout, 12 weeks of drug.
Study: NCT03645902

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Study: NCT02401490

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04029701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruyizhenbao Pill
Description: Ruyizhenbao Pills are provided by Jinhe Tibetan Pharmaceutical Co., Ltd. Chinese national medicine permission number:Z63020289、Z63020064. Medication method: oral 4 pills once, twice a day, 4 weeks in a row.
Study: NCT02307383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactitol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus
Study: NCT04029701

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Ruyizhenbao Pill
Description: Placebo is provided by Jinhe Tibetan Pharmaceutical Co., Ltd.，which is made of malt dextrin as a matrix, similar shape and same color to the Ruyizhenbao Pill. Medication method: oral 4 pills once, twice a day, 4 weeks in a row.
Study: NCT01341002

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transfusion
Description: Red Blood Cells (RBC) Transfusion if SCVO2 \< 70% and guidelines
Study: NCT01103037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAV680
Description: QAV680 500 mg (5 x 100 mg capsules) four times per day
Study: NCT03048318

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arterial Flushing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Portal Flushing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Portal Flushing
Study: NCT01263782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles.
Study: NCT01103037

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: QAV680 Placebo
Description: Placebo to QAV680 5 capsules four times per day
Study: NCT01263782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 by vein on day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 by vein on day 1 of each 21 day cycle.
Study: NCT01341002

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfusion
Description: transfusion based on guidelines
Study: NCT01263782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 by vein on day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 by vein on day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg by vein on day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: 20 mg/kg by vein on day 1 of each 21 day cycle.
Study: NCT02913274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Taxol) eluting angioplasty balloon
Description: Dilatation by a high-pressure conventional angioplasty balloon untill disappearance of the stenosis obstructive area and achievement of technical success. Then dilatation by a DEB of the same size for 2 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-pressure angioplasty balloon
Description: Dilatation by a high-pressure conventional angioplasty balloon untill disappearance of the stenosis obstructive area and achievement of technical success. Then dilatation either by a shame balloon or by a DEB balloon of the same size for 2 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-pressure angioplasty balloon
Description: Dilatation by a high-pressure conventional angioplasty balloon untill disappearance of the stenosis obstructive area and achievement of technical success. Then dilatation either by a shame balloon or by a DEB balloon of the same size for 2 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low-pressure balloon
Description: Dilatation by a high-pressure conventional angioplasty balloon untill disappearance of the stenosis obstructive area and achievement of technical success. Thenn dilatation by a shame balloon i.e conventional low pression balloon of the same size for 2 minutes.
Study: NCT02234830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoseal closure device
Description: Closure device for femoral artery access closure
Study: NCT02857309

Intervention type: DRUG
Group type: OTHER
Intervention: Optimal medical therapy
Description: OMT using standard heart failure (HF) drugs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical therapy
Description: OMT using standard heart failure (HF) drugs
Study: NCT02234830

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angioseal closure device
Description: Closure device for femoral artery access closure
Study: NCT04550325

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kamada Anti-SARS-CoV-2
Description: Anti-SARS-CoV-2 is a preparation of immune gamma globulin manufactured from convalescent plasma of COVID-19 recovered patients, using Kamada's proprietary purification methods
Study: NCT01695824

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LAA occluder
Description: The procedure is performed under transesophageal echocardiographic (TEE) guidance. After a transseptal puncture is performed, a pigtail catheter is maneuvered into the LAA to perform an LAA angiogram. Through the use of a combination of this angiographic and TEE information, a Watchman device, ranging in size between 21 and 33 mm in diameter, is selected. The device comes prepackaged in a catheter-based delivery system that is advanced into the LAA through a 12F transseptal sheath (outer diameter, 14F). Proper positioning and stability of the device are verified by TEE and angiography before device release.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFA ablation
Description: The left atrium (LA) and pulmonary veins (PVs) were explored through a transseptal approach. Real-time three-dimensional (3D) LA maps were reconstructed by using a nonfluoroscopic navigation system (CARTO, Biosense-Webster Inc.). The ipsilateral left and right PVs were encircled in 1 lesion line by circumferential PV isolation. Radiofrequency energy was delivered at 43◦C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43◦C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 seconds. The endpoint of circumferential PV isolation was PV isolation; this was confirmed when Lasso mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from left atrial activity.
Study: NCT00125242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semantic Feature Analysis (SFA)Training
Description: SFA entails having the speech-language pathologist (SLP) guide the participant through generation of pertinent semantic features for pictured treatment items (e.g., category membership, physical description, location of item in context, personal associations, action associated with item). For some participants, treatment items were grouped according to typicality of category membership (e.g,, a robin-typical bird and penguin-atypical bird). Training of atypical items may stimulate a broader semantic activation of the category and thus, may promote greater generalization. Treatment was applied sequentially to sets of items in the context of single-subject, multiple baseline designs. In this way, replication of treatment effects could be evaluated within and across participants. Treatment was administered by certified SLPs three times per week until prescribed accuracy levels were met during nontreatment probes or a maximum number of treatment sessions was completed.
Study: NCT01905293

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feeding Study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feeding Study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feeding Study
Study: NCT02429037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAd-p53
Description: multi-point injections of rAd-p53 into tumor on day 1, 8 and 15 at a dose of 2 × 10\^12 viral particles (VP) in a 21-days cycle.
Study: NCT01435018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide (ET)
Description: Beginning on day one of the chemotherapy cycle, ET was given orally in a dose of 50 mg twice daily for 7 consecutive days for the first cycle. If there was no Grade \>= 2 toxicity attributable to ET after the first cycle, the dose was escalated to 150 mg daily for 7 days in divided doses of 100 mg/50 mg for the second cycle. After the second cycle, if there was no Grade \>= 2 toxicity attributable to ET, the dose was escalated to 100 mg twice daily for 7 days for the third and subsequent cycles.~Treatment with ET was continued for six cycles at the maximum dose achieved or until toxicity requiring discontinuation of study chemotherapy, or the site investigator, after consulting with the protocol CMC, had determined that alternative therapy is required, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin and Vincristine (BV)
Description: BV was administered on day one of each chemotherapy cycle.~Vincristine sulfate was administered at a dose of 2 mg (fixed dose) in a volume of 2 mL over 1 minute into the sidearm of a rapidly flowing intravenous infusion every 3 weeks. The vincristine infusion was followed by bleomycin as detailed below.~Bleomycin sulfate was administered at a dose of 15 units/m\^2 over 10 minutes every 3 weeks.~Treatment with BV was continued for six cycles, or until toxicity requiring discontinuation of study chemotherapy, or the site investigator, after consulting with the protocol CMC, had determined that alternative therapy is required, whichever occurs first.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel (PTX)
Description: Paclitaxel was administered by IV infusion in 200 mL, 250 mL, or 500 mL of 5% dextrose or 0.9%Sodium Chloride for injection at a dose of 100 mg/m\^2 body surface area (BSA) every 3 weeks.
Study: NCT04784117

Intervention type: OTHER
Intervention: Dispatcher protocol change
Description: In the beginning of 2019 dispatcher protocol was changed to shorten the time of death detection
Study: NCT01499121

Intervention type: DRUG
Group type: OTHER
Intervention: Sunitinib
Description: The starting dose will be 50 mg Sunitinib on the 28/14 schedule. In patients that develop ≥ grade-2 toxicity after 2 weeks, therapy will be held for 7 days or resolution before continuing therapy according to the 1st dose/schedule change. In patients that do not develop ≥ grade-2 toxicity, therapy will continue for 1-2 weeks or until ≥ grade-2 toxicity. In patients that develop \> grade-2 toxicity after less than 4 weeks, therapy will be held for 7 days or before continued according to the 1st dose/schedule change. Patients that do develop grade-2 toxicity (but no more) on the 50 mg 28/14 schedule, will remain on schedule but the time off therapy will be reduced to 7 days if toxicity has resolved after a 7-day break. Patients that develop ≤ grade-1 toxicity on the 50 mg 28/14 schedule, will be dose escalated according to protocol.
Study: NCT04043845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib inhibits the function of Bruton's tyrosine kinase (BTK). Ibrutinib blocks signals that stimulate malignant B cells to grow and divide uncontrollably.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3214996
Description: LY3214996 is an extracellular signal-regulated kinase (ERK) inhibitor. ERK inhibitors stop the signal that a cancer cell receives telling it to grow.
Study: NCT01501695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5LGr
Description: Dosage form:Granule Strength:5 gram/sack Dosage:1 sack for patients less than 12 yrs 1.5 sacks for patients 13-18 yrs. Frequency: three times per day. Duration: 8 weeks.
Study: NCT01435018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
Description: The following ART regimens were used:~1. EFV/FTC/TDF (Atripla) 200 mg/300 mg/600 mg orally once daily at bedtime or~2. FTC/TDF 200 mg/300 mg (Truvada) orally once daily at bedtime plus EFV (Stocrin) 600 mg orally once daily at bedtime or~3. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus nevirapine (NVP) 200 mg orally twice daily or~4. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus PI/r at standard dosing or~5. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus integrase inhibitor at standard dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
Description: The following ART regimens were used:~1. EFV/FTC/TDF (Atripla) 200 mg/300 mg/600 mg orally once daily at bedtime or~2. FTC/TDF 200 mg/300 mg (Truvada) orally once daily at bedtime plus EFV (Stocrin) 600 mg orally once daily at bedtime or~3. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus nevirapine (NVP) 200 mg orally twice daily or~4. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus PI/r at standard dosing or~5. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus integrase inhibitor at standard dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
Description: The following ART regimens were used:~1. EFV/FTC/TDF (Atripla) 200 mg/300 mg/600 mg orally once daily at bedtime or~2. FTC/TDF 200 mg/300 mg (Truvada) orally once daily at bedtime plus EFV (Stocrin) 600 mg orally once daily at bedtime or~3. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus nevirapine (NVP) 200 mg orally twice daily or~4. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus PI/r at standard dosing or~5. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus integrase inhibitor at standard dosing
Study: NCT00003118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study: NCT01695824

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFA ablation
Description: The left atrium (LA) and pulmonary veins (PVs) were explored through a transseptal approach. Real-time three-dimensional (3D) LA maps were reconstructed by using a nonfluoroscopic navigation system (CARTO, Biosense-Webster Inc.). The ipsilateral left and right PVs were encircled in 1 lesion line by circumferential PV isolation. Radiofrequency energy was delivered at 43◦C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43◦C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 seconds. The endpoint of circumferential PV isolation was PV isolation; this was confirmed when Lasso mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from left atrial activity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin was discontinued in 45 days after procedure in case of no trombus by TE for Watchman group~All patients in Warfarin group continued to receive Warfarin during hole study period with IMR from II to III.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin was discontinued in 45 days after procedure in case of no trombus by TE for Watchman group~All patients in Warfarin group continued to receive Warfarin during hole study period with IMR from II to III.
Study: NCT03248765

Intervention type: OTHER
Intervention: post-surgical opioid use measured at 1 day and 1 week.
Description: Evaluation of intra-hospital perioperative opioid administration (including intraoperative opioids and Patient Controlled Analgesia (PCA) use). This endpoint is calculated as the total amount of morphine equivalents administered intraoperatively and in the first 24 hours after the end surgery (measured on postoperative day 1).~2) Opioid utilization after discharge from hospital (prescription refills and pills count at subsequent hospital visits). This endpoint is calculated as the total amount of morphine equivalents consumed in the first week after the surgery (measured at 1 week after surgery by electronic questionnaire and verified by direct pill count performed on occasion of the patient's postsurgical visit ).

Intervention type: OTHER
Intervention: post-surgical opioid use measured at 1 day and 1 week.
Description: Evaluation of intra-hospital perioperative opioid administration (including intraoperative opioids and Patient Controlled Analgesia (PCA) use). This endpoint is calculated as the total amount of morphine equivalents administered intraoperatively and in the first 24 hours after the end surgery (measured on postoperative day 1).~2) Opioid utilization after discharge from hospital (prescription refills and pills count at subsequent hospital visits). This endpoint is calculated as the total amount of morphine equivalents consumed in the first week after the surgery (measured at 1 week after surgery by electronic questionnaire and verified by direct pill count performed on occasion of the patient's postsurgical visit ).
Study: NCT04177680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3 pentaenoic acid
Description: Encapsulated omega-3 pentaenoic acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: icosapent ethyl
Description: Encapsulated omega-3 acid ethyl esters
Study: NCT00622011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone and Zotepine for delirium
Description: try risperidone or zotepine in the treatment of delirium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone and Zotepine for delirium
Description: try risperidone or zotepine in the treatment of delirium
Study: NCT00003118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical procedure